CTLA4 and metastatic melanoma: Clinical studies shows that 10% of NSCLC and metastatic melanoma patients treated with CTLA-4 inhibitor develop hypophysitis, and our model shows that the corresponding level of TNF-α about the control level (Tα,ave(70)) is 9.47 pg/ml.